Open AccessResearch update on the association between SFRP5, an anti‐inflammatory adipokine, with obesity, type 2 diabetes mellitus and coronary heart disease
Author(s) -
Wang Di,
Zhang Yaping,
Shen Chengxing
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15023
Subject(s) - adipokine , type 2 diabetes mellitus , obesity , medicine , pathogenesis , type 2 diabetes , diabetes mellitus , disease , inflammation , metabolic syndrome , bioinformatics , immunology , insulin resistance , endocrinology , biology
Secreted frizzled‐related protein 5 (SFRP5), an anti‐inflammatory adipokine secreted by adipocytes, has been demonstrated to exert its anti‐inflammatory effect via antagonizing the non‐canonical wingless‐type family member 5A (WNT5A) signalling pathways. The WNT5A protein, as a potent pro‐inflammatory signalling molecule, is strongly involved in a variety of inflammatory disorders such as obesity, type 2 diabetes mellitus (T2DM) and atherosclerosis. In this review, we systematically outlined the current understanding on the roles of SFRP5 in the pathogenesis of three inflammatory diseases including obesity, T2DM and coronary heart disease (CHD). Our review might stimulate future research using SFRP5 as a promising novel therapeutic target for the treatment of obesity, T2DM and CHD.